Source:http://linkedlifedata.com/resource/pubmed/id/21062313
Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
6
|
pubmed:dateCreated |
2010-11-10
|
pubmed:abstractText |
Koalas (n?=?43) were treated daily for up to 8?weeks with enrofloxacin: 10?mg/kg subcutaneously (s.c.), 5?mg/kg s.c., or 20?mg/kg per os (p.o.); or marbofloxacin: 1.0-3.3?mg/kg p.o., 10?mg/kg p.o. or 5?mg/kg s.c. Serial plasma drug concentrations were determined on day 1 and again at approximately 2?weeks, by liquid chromatography. The median (range) plasma maximum concentrations (C(max) ) for enrofloxacin 5?mg/kg s.c. and 10?mg/kg s.c. were 0.83 (0.68-1.52) and 2.08 (1.34-2.96)??g/mL and the median (range) T(max) were 1.5?h (1-2) and 1?h (1-2) respectively. Plasma concentrations of orally dosed marbofloxacin were too low to be quantified. Oral administration of enrofloxacin suggested absorption rate limited disposition pharmacokinetics; the median (range) C(max) for enrofloxacin 20?mg/kg p.o. was 0.94 (0.76-1.0)??g/mL and the median (range) T(max) was 4?h (2-8). Oral absorption of both drugs was poor. Plasma protein binding for enrofloxacin was 55.4?±?1.9% and marbofloxacin 49.5?±?5.3%. Elevations in creatinine kinase activity were associated with drug injections. Enrofloxacin and marbofloxacin administered at these dosage and routes are unlikely to inhibit the growth of chlamydial pathogens in vivo.
|
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical | |
pubmed:status |
MEDLINE
|
pubmed:month |
Dec
|
pubmed:issn |
1365-2885
|
pubmed:author | |
pubmed:copyrightInfo |
© 2010 Blackwell Publishing Ltd.
|
pubmed:issnType |
Electronic
|
pubmed:volume |
33
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
595-604
|
pubmed:meshHeading |
pubmed-meshheading:21062313-Administration, Oral,
pubmed-meshheading:21062313-Animals,
pubmed-meshheading:21062313-Anti-Bacterial Agents,
pubmed-meshheading:21062313-Female,
pubmed-meshheading:21062313-Fluoroquinolones,
pubmed-meshheading:21062313-Injections, Subcutaneous,
pubmed-meshheading:21062313-Intestinal Absorption,
pubmed-meshheading:21062313-Male,
pubmed-meshheading:21062313-Phascolarctidae
|
pubmed:year |
2010
|
pubmed:articleTitle |
Absorption of enrofloxacin and marbofloxacin after oral and subcutaneous administration in diseased koalas (Phascolarctos cinereus).
|
pubmed:affiliation |
Faculty of Veterinary Science, Sydney Medical School, The University of Sydney, Camperdown, NSW, Australia. joanna.griffith@sydney.edu.au
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't
|